Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, Frederick Lansigan et al.|Clinical Cancer Research|2019Cited by 90
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐<scp>BCR</scp>inhibitor setting: a<scp>UK</scp>wide analysisToby A. Eyre, Amy A. Kirkwood, Satyen H. Gohil et al.|British Journal of Haematology|2019Cited by 79
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R. Wilson, Fiona Miall, Toby A. Eyre et al.|UCL Discovery (University College London)|2022Cited by 76
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic reviewToby A. Eyre, Graham P. Collins, Faouzi Djebbari et al.|Haematologica|2019Cited by 70
Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicityToby A. Eyre, Chris S.R Hatton, Amy A. Kirkwood et al.|British Journal of Haematology|2019Cited by 65